Follow-Up Imaging Guidelines for Patients with Stage III Unresectable NSCLC: Recommendations Based on the PACIFIC Trial

The PACIFIC trial showed a survival benefit with durvalumab through five years in stage III unresectable non-small cell lung cancer (NSCLC). However, optimal use of imaging to detect disease progression remains unclearly defined for this population. An expert working group convened to consider avail...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, Jenny J., Banerji, Shantanu, Blais, Normand, Brade, Anthony, Clelland, Cathy, Schellenberg, Devin, Snow, Stephanie, Wheatley-Price, Paul, Yuan, Ren, Melosky, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137068/
https://www.ncbi.nlm.nih.gov/pubmed/37185402
http://dx.doi.org/10.3390/curroncol30040289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137068/
https://www.ncbi.nlm.nih.gov/pubmed/37185402
http://dx.doi.org/10.3390/curroncol30040289

Ejemplares similares